Direct intra-accumbal infusion of a beta-adrenergic receptor antagonist abolishes WIN 55,212-2-induced aversion

NEUROSCIENCE LETTERS

卷:500

Article

Carvalho, Ana Franky^1,2,3  Van Bockstaele, Elisabeth J.² 

[1] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal

[2] Thomas Jefferson Univ, Farber Inst Neurosci, Dept Neurosci, Philadelphia, PA 19107 USA

[3] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal

关键词: Cannabinoids;    Lithium;    Adrenergic receptors;    Place conditioning;    Aversion;   

DOI  :  10.1016/j.neulet.2011.06.008

来源: Elsevier

【 摘 要 】

The cannabinoid system is known to interact with a variety of neuromodulators in the central nervous system and impacts diverse behaviors. Previous studies have demonstrated that limbic norepinephrine is a critical determinant in the behavioral expression of cannabinoid-induced aversion. The present study was carried out to define the adrenergic receptor subtype involved in mediating cannabinoid-induced behavioral responses. An acute microinjection of the beta 1-adrenergic receptor blocker, betaxolol, directly into the nucleus accumbens (Acb), was able to prevent WIN 55.212-2-induced aversion, but not lithium-induced aversion, as measured in a place conditioning paradigm. These results suggest that noradrenergic transmission in the Acb is important for cannabinoid-induced aversion and that beta-adrenergic antagonists may be effective in counteracting negative side effects of cannabinoid-based agents. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

【 授权许可】

Free